Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 6;9:4.
doi: 10.3389/fnsys.2015.00004. eCollection 2015.

Screening and Personalizing Nootropic Drugs and Cognitive Modulator Regimens in Silico

Free PMC article

Screening and Personalizing Nootropic Drugs and Cognitive Modulator Regimens in Silico

Leslie C Jellen et al. Front Syst Neurosci. .
Free PMC article


The go-to cognitive enhancers of today are those that are widely available rather than optimal for the user, including drugs typically prescribed for treatment of ADHD (e.g., methylphenidate) and sleep disturbances such as narcolepsy (modafinil). While highly effective in their intended therapeutic role, performance gains in healthy populations are modest at best and profoundly inconsistent across subgroups and individuals. We propose a method for in silico screening of possible novel cognitive enhancers followed by high-throughput in vivo and in vitro validation. The proposed method uses gene expression data to evaluate the the collection of activated or suppressed signaling pathways in tissues or neurons of the cognitively enhanced brain. An algorithm maps expression data onto signaling pathways and quantifies their individual activation strength. The collective pathways and their activation form what we term the signaling pathway cloud, a biological fingerprint of cognitive enhancement (or any other condition of interest). Drugs can then be screened and ranked based on their ability to minimize, mimic, or exaggerate pathway activation or suppression within that cloud. Using this approach, one may predict the efficacy of many drugs that may enhance various aspects of cognition before costly preclinical studies and clinical trials are undertaken.

Keywords: cognitive enhancement; drug repositioning; in silico medicine; nootropic; oncofinder; personalized medicine; signalome; signalome profiling.


Figure 1
Figure 1
Using differential signaling pathway activation profiles between cell/tissue culture or mice treated and untreated with known cognitive modulators or genetic models of cognitive enhancement to screen for potential nootropic compounds.

Similar articles

See all similar articles

Cited by 4 articles


    1. Adriani W., Leo D., Greco D., Rea M., di Porzio U., Laviola G., et al. . (2006a). Methylphenidate administration to adolescent rats determines plastic changes in reward-related behavior and striatal gene expression. Neuropsychopharmacology 31, 1946–1956. 10.1038/sj.npp.1300962 - DOI - PubMed
    1. Adriani W., Leo D., Guarino M., Natoli A., Di Consiglio E., De Angelis G., et al. . (2006b). Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual/endocrine parameters in male rats. Ann. N Y Acad. Sci. 1074, 52–57. 10.1196/annals.1369.005 - DOI - PubMed
    1. Aliper A., Csoka A. B., Buzdin A., Jetka T., Roumiantsev S., Moskalev A., et al. (2015). Signaling pathway activation drift during aging: Hutchinson-Gilford progeria syndrome fibroblasts are comparable to normal middle-age and old-age cells. Aging (Albany NY) [Epub ahead of print]. - PMC - PubMed
    1. Beglinger L. J., Tangphao-Daniels O., Kareken D. A., Zhang L., Mohs R., Siemers E. R. (2005). Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study. J. Clin. Psychopharmacol. 25, 159–165. 10.1097/ - DOI - PubMed
    1. Belmonte M. K., Yurgelun-Todd D. A. (2003). Functional anatomy of impaired selective attention and compensatory processing in autism. Brain Res. Cogn. Brain Res. 17, 651–664. 10.1016/s0926-6410(03)00189-7 - DOI - PubMed

LinkOut - more resources